Regeneron Pharmaceuticals, Inc.

Yale University

Institute for Research in Biomedicine (irb)

Regeneran Pharmaceuticals, Inc.

Duke University

Institute for Research in Biomedicine

Cagan Gurer

Andrew J Murphy

Lynn Macdonald

Sean Stevens

Karolina Meagher

Naxin Tu

Vera Voronina

John R McWhirter

Karolina A Hosiawa

O Gavin Thurston

Bindu Varghese

George D Yancopoulos

Faith Harris

Gavin Thurston

Alexander O Mujica

Ella Ioffe

Yingzi Xue

Ka-Man Venus Lai

Richard A Flavell

Markus G Manz

Jose F Rojas

Till Strowig

Noah Palm

Marcel De Zoete

Liang Shan

Dietmar Herndler-Brandstetter

Davor Frleta

Aris I Baras

Israel Lowy

Li-Hsien Wang

Garnett Kelsoe

Barton F Haynes

Christos Kyratsous

Robert Babb

Brinda Prasad

John Mcwhirter

John McWhirter

Noah W Palm

Karolina A Meagher

Markus Gabriel Manz

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin λ light chain variable domain.

Humanized light chain mice

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized a proliferation-inducing ligand gene. Non-human animals and cells that express a human or humanized a proliferation-inducing ligand protein from an endogenous a proliferation-inducing ligand locus are described.

Non-human animals having a humanized a proliferation-inducing ligand gene

The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized β2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.

Genetically modified major histocompatibility complex mice

Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).

Mouse having a humanized cluster of differentiation 47 gene

Genetically modified non-human animals comprising a humanized interleukin-15 (IL-15) gene. Cells, embryos, and non-human animals comprising a human IL-15 gene. Rodents that express humanized or human IL-15 protein.

Humanized IL-15 animals

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

Non-human animals having a humanized signal-regulatory protein gene

Disclosed herein are genetically modified rodent animals comprising in their genome a nucleic acid which comprises a nucleotide sequence encoding a human CR1 polypeptide, wherein the rodent animals display a human-like expression of the human CR1 polypeptide. Also disclosed herein are isolated rodent cells including rodent embryonic stem cells, and rodent tissues. Further disclosed are nucleic acid vectors and methods for making the genetically modified rodent animals, as well as methods of using such genetically modified rodent animals for screening and testing candidate compounds.

Rodent animals expressing human CR1

The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8α, CD8β), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.

Humanized T cell co-receptor mice

Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.

Mouse having a humanized B-cell activating factor gene

Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity FcγR locus, and wherein the mouse is capable of expressing a functional FcRγ-chain. Genetically modified mice are described, including mice that express low affinity human FcγR genes from the endogenous FcγR locus, and wherein the mice comprise a functional FcRγ-chain. Genetically modified mice that express up to five low affinity human FcγR genes on accessory cells of the host immune system are provided.

Methods of using humanized FCγR mice to assay Fc regions

Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin &#x3bb; light chain variable domain.

Genetically modified non-human animals expressing human SIRP&#x3b1; and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRP&#x3b1; and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRP&#x3b1; and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.

Genetically modified non-human animals and methods of use thereof

The invention provides a genetically modified non-human animal that comprises in its genome unrearranged T cell receptor variable gene loci, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified non-human animal and methods of making the same. Various methods of using the genetically modified non-human animal are also provided.

Genetically modified T cell receptor mice

Growing community of inventors

Chappaqua, NY, United States of America

Cagan Gurer